Jarrett Jennifer, CEO of Damora Therapeutics, Purchases 12,500 Shares for $252,875
On September 28, 2026, Jarrett Jennifer, director, president, and CEO of Damora Therapeutics, Inc., acquired 12,500 shares at $20.23 per share, totaling $252,875. The transaction was reported to the SEC via Form 4, which must be filed within two business days.
On September 28, 2026, Jarrett Jennifer, director, president, and CEO of Damora Therapeutics, Inc., purchased 12,500 shares of the company at a price of $20.23 per share, amounting to a total investment of $252,875.
Who is Jarrett Jennifer and what is her actual role at Damora Therapeutics, Inc.
Jarrett Jennifer holds simultaneous roles as director, president, and chief executive officer (CEO) of Damora Therapeutics, Inc., which places her in ultimate responsibility for the company's governance, strategic business decisions, and operational oversight. As a board member, she participates in key decisions regarding research directions, strategic alliances, and capital allocations.
The CEO position grants direct access to confidential information related to clinical trials, unpublished financial results, and negotiations with development partners. This role places Jarrett Jennifer among the legal insidersâindividuals authorized to know facts that could influence the stock price before their public release.
Transaction Details: 12,500 shares at $20.23 each
The Form 4 filed with the Securities and Exchange Commission (SEC) indicates that 12,500 shares were acquired at a per-share price of $20.23, corresponding to the market value of the stock at the time of the transaction. The execution date, recorded as September 28, 2026, is also noted in the official document.
The gross value of the transaction, calculated by multiplying the number of shares by the per-share price, amounts to $252,875. This information appears in the "Transaction Value" section of the form, distinct from the per-share price to avoid confusion between the two financial measures.
Why Insiders Buy Their SharesâPossible Reasons
A director may decide to increase their ownership for several reasons that are not necessarily tied to an expectation of a stock price rise. One common reason is the desire to strengthen their alignment of interests with shareholders, demonstrating personal confidence in the company's strategy.
Tax considerations may also play a role, such as planning for the recognition of capital gains or optimizing asset allocation. In some cases, the purchase serves to diversify an already heavily invested portfolio or to rebalance between liquid assets and equities.
It is also possible that the transaction addresses personal liquidity needs, such as funding a private project or settling tax obligations. Finally, the acquisition may be linked to the exercise of stock purchase options or the receipt of shares under a long-term incentive plan, triggering an immediate buyback operation.
How Individual Investors Monitor Form 4 Filings
Form 4 filings are published daily on the SEC's EDGAR platform, accessible for free via its official website. Financial data aggregators or portfolio tracking applications can automatically extract insider transactions and present them as filtered lists by company or insider.
Investors can set up custom alerts to be notified immediately when a director or board member executes a transaction, providing real-time insight into the company's internal activity. However, it's important to note that Form 4 filings only include transaction size and price, without detailed explanations.
Additionally, the two-day business window between the transaction and its filing creates a slight temporal lag, meaning markets may have already partially integrated the information before it becomes publicly available. Individual investors should combine Form 4 analysis with other information sources, such as quarterly reports, press releases, and sector analyses, to form an informed opinion.
